Aytu BioPharma (NASDAQ:AYTU) Releases Quarterly Earnings Results, Misses Estimates By $0.37 EPS

Aytu BioPharma (NASDAQ:AYTU) posted its quarterly earnings data on Thursday. The company reported ($0.82) EPS for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.37), Zacks reports. Aytu BioPharma had a negative return on equity of 31.31% and a negative net margin of 14.60%.

Aytu BioPharma Trading Up 17.2 %

NASDAQ:AYTU opened at $2.85 on Friday. The company has a 50-day moving average of $2.53 and a 200-day moving average of $2.83. Aytu BioPharma has a twelve month low of $1.66 and a twelve month high of $3.50. The firm has a market cap of $17.01 million, a price-to-earnings ratio of -1.08 and a beta of -1.43.

Aytu BioPharma Company Profile

Aytu Biopharma, Inc, a commercial-stage pharmaceutical company, focuses on commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company operates through two segments: Rx segment and Consumer Health segment. The Rx segment offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years and older, and Cotempla XR-ODT for patients from six to seventeen years old.